NZ510425A - Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV) - Google Patents

Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV)

Info

Publication number
NZ510425A
NZ510425A NZ51042599A NZ51042599A NZ510425A NZ 510425 A NZ510425 A NZ 510425A NZ 51042599 A NZ51042599 A NZ 51042599A NZ 51042599 A NZ51042599 A NZ 51042599A NZ 510425 A NZ510425 A NZ 510425A
Authority
NZ
New Zealand
Prior art keywords
hsv
gd2t
herpes simplex
simplex virus
vaccine
Prior art date
Application number
NZ51042599A
Other languages
English (en)
Inventor
Moncef Mohammed Slaoui
Pierre Vandepapeliere
Original Assignee
Smithkline Beecham Biolog S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ510425(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog S filed Critical Smithkline Beecham Biolog S
Publication of NZ510425A publication Critical patent/NZ510425A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ51042599A 1998-09-11 1999-09-08 Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV) NZ510425A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use
PCT/EP1999/006623 WO2000015255A1 (en) 1998-09-11 1999-09-08 Vaccine against sexually transmitted diseases

Publications (1)

Publication Number Publication Date
NZ510425A true NZ510425A (en) 2003-04-29

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ51042599A NZ510425A (en) 1998-09-11 1999-09-08 Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV)

Country Status (28)

Country Link
EP (1) EP1109574B1 (https=)
JP (1) JP2002524532A (https=)
KR (1) KR100777896B1 (https=)
CN (2) CN1325311A (https=)
AR (1) AR021798A1 (https=)
AT (1) ATE392214T1 (https=)
AU (1) AU744989B2 (https=)
BR (1) BR9913630A (https=)
CA (1) CA2343399C (https=)
CO (1) CO5090882A1 (https=)
CY (1) CY1108147T1 (https=)
CZ (1) CZ302808B6 (https=)
DE (1) DE69938555T2 (https=)
DK (1) DK1109574T3 (https=)
ES (1) ES2304068T3 (https=)
GB (1) GB9819898D0 (https=)
HU (1) HUP0104297A3 (https=)
IL (1) IL141843A0 (https=)
MY (1) MY122216A (https=)
NO (1) NO329522B1 (https=)
NZ (1) NZ510425A (https=)
PL (1) PL199545B1 (https=)
PT (1) PT1109574E (https=)
SI (1) SI1109574T1 (https=)
TR (1) TR200100948T2 (https=)
TW (1) TWI225790B (https=)
WO (1) WO2000015255A1 (https=)
ZA (1) ZA200101987B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CA2843854A1 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
HK1037978A1 (en) 2002-03-01
CZ2001887A3 (cs) 2001-10-17
EP1109574B1 (en) 2008-04-16
HUP0104297A3 (en) 2004-10-28
MY122216A (en) 2006-03-31
PL346651A1 (en) 2002-02-25
CA2343399A1 (en) 2000-03-23
TWI225790B (en) 2005-01-01
DK1109574T3 (da) 2008-06-30
DE69938555D1 (de) 2008-05-29
BR9913630A (pt) 2001-05-22
PL199545B1 (pl) 2008-09-30
GB9819898D0 (en) 1998-11-04
IL141843A0 (en) 2002-03-10
CZ302808B6 (cs) 2011-11-23
ES2304068T3 (es) 2008-09-01
PT1109574E (pt) 2008-06-12
AU744989B2 (en) 2002-03-07
KR100777896B1 (ko) 2007-11-27
KR20010075049A (ko) 2001-08-09
NO329522B1 (no) 2010-11-01
EP1109574A1 (en) 2001-06-27
NO20011193L (no) 2001-05-09
AU5975299A (en) 2000-04-03
CA2343399C (en) 2010-08-03
ZA200101987B (en) 2002-05-09
DE69938555T2 (de) 2009-06-10
ATE392214T1 (de) 2008-05-15
TR200100948T2 (tr) 2001-07-23
SI1109574T1 (sl) 2008-08-31
JP2002524532A (ja) 2002-08-06
WO2000015255A1 (en) 2000-03-23
CY1108147T1 (el) 2014-02-12
AR021798A1 (es) 2002-08-07
CN1325311A (zh) 2001-12-05
CN101130070A (zh) 2008-02-27
HUP0104297A2 (hu) 2002-03-28
CO5090882A1 (es) 2001-10-30
NO20011193D0 (no) 2001-03-08

Similar Documents

Publication Publication Date Title
NZ510425A (en) Vaccine comprising glycoprotein D (gD2t) against herpes simplex virus (HSV)
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
AR025502A1 (es) Composicion de vacuna adecuada para usar en el tratamiento o la profilaxis de infecciones de virus del papiloma humano e infecciones de virus del herpes simple.
MY135965A (en) Vaccine against hepatitis b and herpes simplex virus
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
IT1241119B (it) Vaccino di poxvirus ricombinante di herpesvirus
NZ517686A (en) Bovine vaccine formula comprising plasmid or plasmids containing gB and gD genes from the bovine herpesvirus
WO1990002803A3 (en) Viral vaccines
BR9907283A (pt) Vìrus do herpes simples, uso de um vìrus do herpes simples, composição farmacêutica, e, processos para estudar a função de gene heterólogo em uma célula de mamìfero e para produzir um vìrus do herpes simples
CA2025923A1 (en) Stop for concrete formwork
AU1019088A (en) Retaining device
GB9306731D0 (en) Vaccines
ES2084270T3 (es) Bayerita conteniendo silice o eta-oxido de aluminio y catalizadores de cracking.
MX9306989A (es) Alumina estabilizada con lantano y su procedimiento de elaboracion.
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
AU4001997A (en) Immune-enhancing agent for therapeutic use in immunocompromised hosts
AU4303493A (en) Use of zona pellucida glycoproteins for immunocontraception
AU8545391A (en) The gene encoding equine herpesvirus type 1 glycoprotein d, its gene product, antibodies and their uses
EP0389286A3 (en) Recombinant cytomegalovirus vaccine
IL91628A0 (en) Viral vaccines
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
EP0351876A3 (en) Composition for potentiating vaccination effect
Hall et al. Bovine trichomonas vaccine compositions
Tedde et al. Enkephalin and vasoactive phoenomena in the capillaries of the human chorionic villi
O'Callaghan Vaccine against equine herpesvirus type 1

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired